August 06, 2025

Could Saliva Replace Blood for Cancer Screening?

Ultra-sensitive Bluetooth biosensor detects breast cancer markers HER2 and CA15-3 in saliva within one second

Conexiant

July 31, 2025

Fluorescent Agent Enables Clearer Nerve Visualization

A phase 1 clinical trial found that rizedisben, a fluorescent agent targeting myelin, enabled sustained nerve visualization during robotic prostate surgery at a 3.0 mg/kg dose with minimal side effects.

Conexiant

April 01, 2025

FDA Approves Freeze-Dried Jynneos Vaccine

Bavarian Nordic’s freeze-dried Jynneos vaccine offers logistical advantages over the liquid-frozen version, supporting long-term U.S. stockpiling and public health preparedness.

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

June 06, 2025

Lower-Dose Treatment Effective in Anal Cancer Trial, Study

In a recent clinical trial, researchers found that a reduced-dose chemoradiotherapy regimen for early-stage anal cancer may be comparable to standard treatment in achieving short-term tumor response, while causing fewer serious side effects.

Conexiant

April 24, 2025

Vitamin D Multifaceted CRC Immunomodulator Revealed

"Vitamin D enhances immune organ functions such as the spleen and lymph nodes, and boosts T-cell activity, which is essential in defending the body against tumors."

Conexiant

April 25, 2025

FDA Approves Penpulimab-kcqx for NPC

The FDA approved penpulimab-kcqx for first line and previously treated recurrent or metastatic non-keratinizing nasopharyngeal carcinoma.

Conexiant

June 19, 2025

AI Models Predict Lung Cancer Risk Better

A new review finds AI-based models more accurate than traditional regression models at predicting lung cancer risk, especially when using low-dose CT imaging data.

Conexiant

May 16, 2025

FDA Approves PD-1–Targeted Monoclonal Antibody for SCAC

The FDA has approved Zynyz (retifanlimab-dlwr) as the first programmed death receptor-1 inhibitor for first-line treatment of advanced squamous cell carcinoma of the anal canal.

Conexiant